Studies performed in the past two decades have unequivocally shown that several of the components of the metabolic syndrome are associated with indirect and direct markers of adrenergic overdrive. This is the case for hypertension and obesity, in which resting tachycardia, elevated plasma norepinephrine values, increased sympathetic nerve traffic, as well as augmented levels of total and regional norepinephrine spillover have been reported. This is also the case for insulin resistance, i.e. a metabolic condition frequently complicating the various components of the pathological condition identified as the 'metabolic syndrome'. After briefly describing the epidemiological and the cardiovascular risk profile of the disease, this paper will examine the behaviour of the sympathetic nervous system in the metabolic syndrome as well as the mechanisms potentially responsible for this neurogenic abnormality. This will be followed by an analysis of the role played by neuroadrenergic factors in disease progression as well as in the pathogenesis of its complications. Finally, the therapeutic implications of these findings will be highlighted.

Mancia, G., Bousquet, P., Elghozi, J., Esler, M., Grassi, G., Julius, S., et al. (2007). The sympathetic nervous system and the metabolic syndrome. JOURNAL OF HYPERTENSION, 25(5), 909-920 [10.1097/HJH.0b013e328048d004].

The sympathetic nervous system and the metabolic syndrome

MANCIA, GIUSEPPE;GRASSI, GUIDO;
2007

Abstract

Studies performed in the past two decades have unequivocally shown that several of the components of the metabolic syndrome are associated with indirect and direct markers of adrenergic overdrive. This is the case for hypertension and obesity, in which resting tachycardia, elevated plasma norepinephrine values, increased sympathetic nerve traffic, as well as augmented levels of total and regional norepinephrine spillover have been reported. This is also the case for insulin resistance, i.e. a metabolic condition frequently complicating the various components of the pathological condition identified as the 'metabolic syndrome'. After briefly describing the epidemiological and the cardiovascular risk profile of the disease, this paper will examine the behaviour of the sympathetic nervous system in the metabolic syndrome as well as the mechanisms potentially responsible for this neurogenic abnormality. This will be followed by an analysis of the role played by neuroadrenergic factors in disease progression as well as in the pathogenesis of its complications. Finally, the therapeutic implications of these findings will be highlighted.
Articolo in rivista - Articolo scientifico
central sympatholytic drugs; hypertension; insulin; metabolic syndrome; obesity; sleep apnoea; sympathetic nervous system
English
mag-2007
25
5
909
920
none
Mancia, G., Bousquet, P., Elghozi, J., Esler, M., Grassi, G., Julius, S., et al. (2007). The sympathetic nervous system and the metabolic syndrome. JOURNAL OF HYPERTENSION, 25(5), 909-920 [10.1097/HJH.0b013e328048d004].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/5037
Citazioni
  • Scopus 326
  • ???jsp.display-item.citation.isi??? 296
Social impact